scholarly journals A case of concomitant uterine adenocarcinoma in situ and ovarian clear cell adenocarcinoma found in uterine cervical cytology.

1999 ◽  
Vol 38 (4) ◽  
pp. 358-362
Author(s):  
Yuji SHIOZAWA ◽  
Yukio ISHII ◽  
Kimie YAMAGISHI ◽  
Yoshiya THOME ◽  
Yoshio UEI
Keyword(s):  
Clear Cell ◽  
Cervical Cytology ◽  
Clear Cell Adenocarcinoma ◽  
Adenocarcinoma In Situ ◽  
Ovarian Clear Cell Adenocarcinoma ◽  
Uterine Adenocarcinoma

Cervical Cytology Screening History of Women Diagnosed with Adenocarcinoma in Situ of the Cervix

2004 ◽  
Vol 48 (5) ◽  
pp. 595-600 ◽  
Author(s):  
Heather Mitchell ◽  
Jane Hocking ◽  
Marion Saville
Keyword(s):  
Cervical Cytology ◽  
Adenocarcinoma In Situ ◽  
History Of ◽  
Cytology Screening ◽  
Screening History

Two cases of ovarian clear cell adenocarcinoma producing estradiol

2012 ◽  
Vol 62 (3) ◽  
pp. 216-218 ◽  
Author(s):  
Tomohito Tanaka ◽  
Takayoshi Kanda ◽  
Satoru Munakata ◽  
Shigeki Fujita ◽  
Masahide Ohmichi
Keyword(s):  
Clear Cell ◽  
Clear Cell Adenocarcinoma ◽  
Ovarian Clear Cell Adenocarcinoma

scholarly journals Obstructive Uropathy as a Major Presentation of Ovarian Clear Cell Adenocarcinoma

2008 ◽  
Vol 47 (1) ◽  
pp. 116-119
Author(s):  
Yen-Hua Huang ◽  
Tien-Shan Wei ◽  
Pao-Jen Chen ◽  
Shuenn-Dyh Chang ◽  
Tony Wing-Cheong Chi ◽  
...  
Keyword(s):  
Clear Cell ◽  
Obstructive Uropathy ◽  
Clear Cell Adenocarcinoma ◽  
Ovarian Clear Cell Adenocarcinoma

Validation of the Histologic Grading for Ovarian Clear Cell Adenocarcinoma

2011 ◽  
Vol 0 (0) ◽  
pp. 129-138 ◽  
Author(s):  
Sohei Yamamoto ◽  
Atsuko Kasajima ◽  
Masashi Takano ◽  
Nobuo Yaegashi ◽  
Hiroyuki Fujiwara ◽  
...  
Keyword(s):  
Clear Cell ◽  
Clear Cell Adenocarcinoma ◽  
Ovarian Clear Cell Adenocarcinoma ◽  
Histologic Grading

Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma

2008 ◽  
Vol 18 (5) ◽  
pp. 934-936 ◽  
Author(s):  
J. A. Rauh-Hain ◽  
R. T. Penson
Keyword(s):  
Kinase Inhibitor ◽  
Clear Cell ◽  
Growth Factor Receptor ◽  
Cystic Degeneration ◽  
Clear Cell Adenocarcinoma ◽  
Vascular Endothelial ◽  
Ovarian Clear Cell Adenocarcinoma ◽  
Stage Ia ◽  
Endothelial Growth Factor ◽  
Similar Gene

Ovarian clear cell adenocarcinoma (OCCA) is a unique biological subtype of epithelial ovarian cancer, with a similar gene profile to renal cell carcinoma (RCC). Sunitinib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with proven antitumor activity in RCC and a rational biological option for treatment of OCCA. A 60-year-old woman presented with recurrent and refractory stage IA OCCA, after 9 years of remission. Sunitinib was initiated as fifth-line chemotherapy, associated with cystic degeneration of liver metastasis and a short downward trend in her CA125 level. Recurrent and refractory OCCA may respond to Sunitinib. Clinical trials are needed to objectively confirm these findings, as benefit may be limited in patients with extensively pretreated tumors

Sign in / Sign up

Export Citation Format

Share Document